These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35060610)

  • 1. Pilot Verification of a Novel Approach to Remove Electrophoretic Interference of the Therapeutic Monoclonal Antibody Daratumumab.
    Baloda V; Shurin MR; Wheeler SE
    J Appl Lab Med; 2022 Jun; 7(4):910-915. PubMed ID: 35060610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and Management of Therapeutic Monoclonal Antibody Interference in Monoclonal Gammopathy Monitoring.
    Liu L; Wertz WJ; Kondisko A; Shurin MR; Wheeler SE
    J Appl Lab Med; 2020 Jan; 5(1):29-40. PubMed ID: 32445341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.
    McCudden C; Axel AE; Slaets D; Dejoie T; Clemens PL; Frans S; Bald J; Plesner T; Jacobs JF; van de Donk NW; Moreau P; Schecter JM; Ahmadi T; Sasser AK
    Clin Chem Lab Med; 2016 Jun; 54(6):1095-104. PubMed ID: 27028734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA).
    van de Donk NW; Otten HG; El Haddad O; Axel A; Sasser AK; Croockewit S; Jacobs JF
    Clin Chem Lab Med; 2016 Jun; 54(6):1105-9. PubMed ID: 26812873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay.
    Rosenberg AS; Bainbridge S; Pahwa R; Jialal I
    Clin Biochem; 2016 Oct; 49(15):1202-1204. PubMed ID: 27475249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference.
    Noori S; Verkleij CPM; Zajec M; Langerhorst P; Bosman PWC; de Rijke YB; Zweegman S; VanDuijn M; Luider T; van de Donk NWCJ; Jacobs JFM
    Clin Chem Lab Med; 2021 Nov; 59(12):1963-1971. PubMed ID: 34392637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tixagevimab Plus Cilgavimab Does Not Affect the Interpretation of Electrophoretic and Free Light Chain Assays.
    Baloda V; McCreary EK; Goscicki BK; Shurin MR; Wheeler SE
    Am J Clin Pathol; 2023 Jan; 159(1):10-13. PubMed ID: 36469049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Application of Hydrashift 2/4 daratumumab assay in eliminating interference of daratumumab on serum immunofixation electrophoresis].
    Xu S; Liu Y; Wen L; Zhao L; Deng X; Rong R; Lu J
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):840-845. PubMed ID: 34788924
    [No Abstract]   [Full Text] [Related]  

  • 9. Complete Depletion of Daratumumab Interference in Serum Samples from Plasma Cell Myeloma Patients Improves the Detection of Endogenous M-Proteins in a Preliminary Study.
    Vakili H; Koorse Germans S; Dong X; Kansagra A; Patel H; Muthukumar A; Hashim IA
    Diagnostics (Basel); 2020 Apr; 10(4):. PubMed ID: 32295157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitigating the interference of Daratumumab with immunofixation electrophoresis. A single-center experience using Hydrashift 2/4 kit.
    Duek A; Lellouche E; Ben Baruch S; Mashiach R; Segman Y; Bryk G; Leiba M
    Isr Med Assoc J; 2022 Oct; 24(10):629-633. PubMed ID: 36309856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case report: serological testing interference of daratumumab (anti-CD38) therapy in multiple myeloma.
    Rabut É; Castro-Fernandez A; Le Gall V; Meknache N
    Ann Biol Clin (Paris); 2017 Jun; 75(3):351-355. PubMed ID: 28540859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of isatuximab-derived interference in serum protein electrophoresis and immunofixation, and an absence of sustained in vivo interference due to belantamab mafodotin and denosumab.
    Jimenez A; Scholl AR; Wang B; Schilke M; Carlsen ED
    Clin Biochem; 2024 May; 127-128():110761. PubMed ID: 38565341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel approach to remove interference of therapeutic monoclonal antibody with serum protein electrophoresis.
    Liu L; Shurin MR; Wheeler SE
    Clin Biochem; 2020 Jan; 75():40-47. PubMed ID: 31669513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay.
    Thoren KL; Pianko MJ; Maakaroun Y; Landgren CO; Ramanathan LV
    J Appl Lab Med; 2019 Mar; 3(5):857-863. PubMed ID: 31639760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying therapeutic monoclonal antibodies using target protein collision electrophoresis reflex assay to separate the wheat from the chaff.
    Teuwen JTJ; Ritzen LFL; Knapen-Portz YM; Ludwiczek PK; Damoiseaux JGMC; van Beers JJBC; de Boer D
    J Immunol Methods; 2023 Nov; 522():113552. PubMed ID: 37652294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evusheld, a SARS-CoV-2 spike protein-directed attachment inhibitor, appears in serum protein electrophoresis and immunofixation: a case study.
    Shah SK; Hagrass HA
    Lab Med; 2023 Nov; 54(6):e201-e203. PubMed ID: 37707512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrophoretic patterns post daratumumab.
    Sheldon J; Wheeler RD; Powles R
    Ann Clin Biochem; 2018 Mar; 55(2):299-301. PubMed ID: 28490184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of M-protein detection on the response evaluations of patients undergoing treatment with the IgG-κ monoclonal antibodies daratumumab or isatuximab, and discrepancies between immunofixation electrophoresis (IFE) systems and reagents.
    Shirouchi Y; Kaihara K; Sekita T; Amano N; Nakayama K; Miyake K; Abe H; Oinuma H; Maruyama D
    Cancer Med; 2024 Aug; 13(16):e70128. PubMed ID: 39177082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A thin-film interferometry-based label-free immunoassay for the detection of daratumumab interference in serum protein electrophoresis.
    Luo YR; Chakraborty I; Zuk RF; Lynch KL; Wu AHB
    Clin Chim Acta; 2020 Mar; 502():128-132. PubMed ID: 31883925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of an in-house trypsin-based method to resolve the interference of daratumumab.
    Ibeh N; Baine I; Rudon LF; Lomas-Francis C; Jhang JS; Galdon P; Westhoff CM; Velliquette RW; Arinsburg SA
    Transfusion; 2021 Oct; 61(10):3000-3007. PubMed ID: 34472116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.